Nanjing Leads Biolabs Reports 55% Response Rate for LBL-024 in Biliary Tract Cancer Study

PUBT · 1d ago
Nanjing Leads Biolabs Reports 55% Response Rate for LBL-024 in Biliary Tract Cancer Study
  • Nanjing Leads Biolabs published six study abstracts covering LBL-024 and LBL-034 for the 2026 European Society for Medical Oncology meeting.
  • Updated results will be presented in three oral presentations, including one late-breaking abstract.
  • LBL-024 showed durable responses and encouraging survival trends as first-line treatment for advanced extrapulmonary neuroendocrine carcinoma, without severe liver toxicity.
  • Early biliary tract cancer results showed tumor responses with no new safety signals; follow-up remained limited.
  • LBL-034 produced deep, durable responses in heavily pretreated multiple myeloma patients, with few severe cytokine release events; a Phase III trial is being prepared.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261019-12376149), on October 19, 2026, and is solely responsible for the information contained therein.